Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 258

The DOI matches its Crossref record.

Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides

Heppeler, A., Froidevaux, S., Eberle, A., Maecke, H.·2000·Current Medicinal Chemistry

Abstract

Receptor targeting with radiolabeled peptides has become very important in nuclear oncology in the past few years. The most frequently used peptides in the clinic are analogs of somatostatin (SRIF), e.g. OctreoScan, which contain chelators for the radioisotopes 111 In, 86Y, 90 Y, 67Ga, 68Ga and 64Cu or for 99m Tc and 188Re. and were labelled with the halogens 123I and 18F. Radiolabeled analogs of a-melanocyte-stimulating hormone (a-MSH), neurotensin, vasoactive intestinal peptide (VIP), bombesin (BN), substance P (SP) and gastrin/cholecystokinin (CCK) are also being developed, evaluated in vitro and in vivo and tested for clinical application. This review focuses on the expression in tumors and the regulation of receptors for these neuropeptides as well as the development of novel chelator-peptide conjugates suitable for in vivo scintigraphy or internal radiotherapy. The state of the art of radiopeptide pharmaceuticals is illustrated with four SRIF analogs, modified with the macrocyclic chelator 1, 4, 7, 10-tetraazacyclododecane- 1, 4, 7, 10-tetraacetic acid (DOTA) (D-Phe 1 )-octreotide (DOTAOC), [D-Phe 1 , Tyr 3 )-octreotide (DOTATOC), vapreotide (DOTAVAP) and lanreotide (DOTALAN). DOTA is almost a universal chelator capable of strongly encapsulating hard metals such as 111 In and 67 Ga for Single Photon Emission Tomography (SPET), 68 Ga, 86 Y and 64 Cu for Positron Emission Tomography (PET) as well as 90 Y for receptor-mediated radionuclide therapy and radiolanthanides which exhibit different interesting decay schemes. From biodistribution studies in experimental animals and from clinical data it is concluded that DOTATOC is currently the most suitable SRIF radiopeptide with the best potential in the clinic. Keywords: radiopeptides, melanocyte stimulating hormone MSH, neurotensin, vasoactive, tetraazacyclododecane 1 4 7 10 tetraacetic acid DOTA, D phe 1 octerotide DOTAOC D Phe1 Tyr3, vapreotide DITAVAP, lanreodtide DOTALAN, positron emission tomography PET, radioiodiantion fluorination, diethylenetriaminepentacetic acid DTPA, bifunctional chelating BFCs, melanocyte stimulating hormonev, vasoactive intestinal peptide, subtance P, cholecystokinin B gastrin, bombesin

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/0929867003374516

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 258

Metadata

Authors
Heppeler, A., Froidevaux, S., Eberle, A., & Maecke, H.
Venue
Current Medicinal Chemistry
Published
2000-09-01
Volume
7
Issue
9
Pages
971-994
ISSN
0929-8673 (ISSN-L)
OpenAlex
W2169983485
Cited by
258
References
0
FWCI
11.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides. https://app.cochat.ai/papers/10.2174/0929867003374516
The paper
Heppeler, A., Froidevaux, S., Eberle, A., & Maecke, H. (2000). Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides. Current Medicinal Chemistry. https://doi.org/10.2174/0929867003374516

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.